Imaging tools to visualize immune response

effective and a few may develop adverse reaction to the immunotherapy. CellSight's PET tracer can help determine if a patient is immune ready or needs immune priming prior to the start of immunotherapy. Additionally, an on-treatment scan can help assess immunotherapy response early in the treatment cycle.
Cancer immunotherapies that harness the body's immune system to help fight cancer do not work for everyone; in fact, success rates can be as low as 20%! Many patients seem to get worse before symptoms ease and clinical benefit can be observed. Some patients may discontinue treatment too early, some continue treatment even though it may not be

Latest News

July 12th, 2023
CellSight's collaborative work with UCSF and Stanford that highlights [18F]F-AraG's potential in cardiovascular imaging won 2nd place in the Cardiovascular track at SNNMI 2023 in Chicago.

February 1, 2022
Immunooncology Symposium, Center for Translation Cancer Research, Western University. "Towards in vivo Immunoscore: Assessing Systemic Immune Response with [18F]F-AraG".

November 14, 2021
SITC 2021 poster presentation. AI-assisted whole-body assessment of immunotherapy response using [18F]F-AraG, a PET agent for activated T cells.

October 5th, 2021
WMIC Spotlight Session presentation. The other ImmunoPET: Visualizing T cell Activity with [18F]F-AraG.

April 9, 2021
UCSF researchers publish "Longitudinal imaging of T-cells and inflammatory demyelination in a preclinical model of multiple sclerosis using [18F]F-AraG PET and MRI" in Journal of Nuclear Medicine

November 11, 2020
"[18F]F-AraG PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy" published in Journal of Nuclear Medicine

May 4, 2020
CellSight partners with IAG, Image Analysis Group, for advanced imaging methodologies to enhance drug development

November 5, 2019
Clinical trial open for patients with triple negative breast cancer and head & neck carcinoma treated with Abbvie's ABBV-368 as a single agent or in combination at UC Davis, Stanford & Yale

May 7, 2019
"Imaging of activated T cells as an early predictor of immune response to anti-PD-1 therapy" published in Cancer Research